Rilvegostomig(Rilvegostomig) - 药物靶点：PD-1 x TIGIT_在研适应症：肌层浸润性膀胱尿路上皮癌，食管腺癌，Claudin 18.2阳性 / HER2阴性的实体瘤_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

AZD 2936、AZD-2936

靶点

PD-1 x TIGIT

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)、TIGIT抑制剂(T细胞免疫球蛋白ITIM结构域抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [3]

在研适应症

肌层浸润性膀胱尿路上皮癌食管腺癌Claudin 18.2阳性 / HER2阴性的实体瘤+ [44]

非在研适应症-

原研机构

AstraZeneca PLC

在研机构

AstraZeneca PLCAstraZeneca Nijmegen BVAstraZeneca AB

+ [3]

非在研机构-

权益机构

AstraZeneca PLC

MedImmune LLC

Compugen Ltd.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 18899517L

来源: *****

Sequence Code 18899526H

来源: *****

Sequence Code 719888445H

来源: *****

Sequence Code 719888446L

来源: *****

关联

36

项与 Rilvegostomig 相关的临床试验

CTIS2025-523599-21-00

/ Not yet recruiting临床2期

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

开始日期2027-01-29

申办/合作机构

AstraZeneca AB

NCT07431281

/ Recruiting临床3期

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

开始日期2026-02-03

申办/合作机构

AstraZeneca PLC

NCT07221253

/ Recruiting临床3期

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

开始日期2025-12-04

申办/合作机构

AstraZeneca PLC

100 项与 Rilvegostomig 相关的临床结果

登录后查看更多信息

100 项与 Rilvegostomig 相关的转化医学

登录后查看更多信息

100 项与 Rilvegostomig 相关的专利（医药）

登录后查看更多信息

5

项与 Rilvegostomig 相关的文献（医药）

2026-01-01·JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer

Article

作者: Lim, Eric ; Forcina, Alessandra ; Opitz, Isabelle ; Yanagawa, Jane ; Batig, Anastasiya ; Harpole, David ; Felip, Enriqueta ; Tsutani, Yasuhiro ; Jones, David R ; Lyfar, Pavlo ; Bodla, Shankar ; Dacic, Sanja ; Ganti, Apar Kishor ; Tan, Daniel S W

BACKGROUND:

Five-year disease recurrence rates for patients with stage I non-small cell lung cancer (NSCLC) postsurgery are variable (15%-40%). There is an urgent need for novel biomarker strategies to identify high-risk patients who may benefit from adjuvant treatment. High-risk pathologic features, including high-grade histology and lymphovascular or visceral pleural invasion, serve as independent risk factors for worse outcomes. Preoperative circulating tumor DNA (ctDNA) detection is also correlated with poorer outcomes in stage I NSCLC. Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate composed of a humanized anti-TROP2 antibody conjugated to a potent topoisomerase I inhibitor via a plasma-stable linker, and rilvegostomig, an Fc-reduced monovalent bispecific humanized IgG1 antibody targeting both PD-1 and TIGIT receptors, have shown promise in NSCLC studies. Combining Dato-DXd with rilvegostomig may improve treatment outcomes in selected patients with stage I NSCLC.

METHODS:

TROPION-Lung12 (NCT06564844) is a phase 3 randomized study enrolling approximately 660 patients with stage I adenocarcinoma without actionable genomic alterations who have undergone complete surgical resection. Eligible patients must have preoperative ctDNA-positive status or 1 or more high-risk pathologic features. Patients will be randomized 2:1:2 to receive Dato-DXd (6 mg/kg intravenously [IV] every 3 weeks) plus rilvegostomig (750 mg IV every 3 weeks) for 4 cycles, followed by rilvegostomig (up to 12 months/18 cycles total), rilvegostomig alone (up to 12 months/18 cycles total), or standard of care (SoC) for up to 12 months. The primary endpoint is disease-free survival, assessed using blinded independent central review according to RECIST v1.1, with key secondary endpoints including overall survival, for the Dato-DXd plus rilvegostomig arm versus the SoC arm.

POSTGRADUATE MEDICAL JOURNAL

Retraction of: Volrustomig/Rilvegostomig related “triple M”—myasthenia gravis and overlap syndrome

Article

Frontiers in Oncology

Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

[This corrects the article DOI: 10.3389/fonc.2025.1721624.].

331

项与 Rilvegostomig 相关的新闻（医药）

2026-07-21

·PRNewswire

Compugen to Participate in BTIG Biotechnology Conference 2026

HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the BTIG Biotechnology Conference 2026 taking place virtually from July 28-29, 2026. Please reach out to your BTIG representative to request a meeting. A replay for this event will not be available. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company Contact: Lindsey Trickett Head of Investor Relations and Corporate Communications Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

临床1期引进/卖出免疫疗法临床2期

2026-07-20

·PRNewswire

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company Contact: Lindsey Trickett Head of Investor Relations and Corporate Communications Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

临床1期引进/卖出免疫疗法财报临床2期

2026-07-16

·新浪医药

BI 恩格列净大卖 57 亿欧元；强生Q2销售额增长6.6%；康诺亚首次扭亏为盈；海思科净利润暴涨超 500%| 2026 H1 财报

近日，各大药企陆续发布H1或Q2财报。 BI 恩格列净大卖 57 亿欧元 7 月 15 日，勃林格殷格翰发布 2026 年上半年财报。报告期内，勃林格殷格翰净销售额增长 16.2%，达到 158 亿欧元。其中，人用药品业务贡献 131 亿欧元，动物保健业务贡献 26 亿欧元。来源：企业官网上半年，在新产品上市的推动下，人用药品销售额增长 20.1%，达到 131 亿欧元。成熟产品恩格列净（用于治疗慢性肾病、2 型糖尿病和心力衰竭的）仍然是主要的增长动力，上半年净销售额达 57 亿欧元。恩格列净的增长得益于其庞大且不断增长的患者群体，以及美国定价和报销环境的变化，这些因素共同推动了销量的显著增长。勃林格殷格翰最新推出的产品那米司特和宗艾替尼也取得了成功，尤其是在美国。那米司特用于治疗特发性肺纤维化（IPF）和进行性肺纤维化（PPF），其强劲的市场表现反映了该疾病领域对新治疗方案的迫切需求，因为多年来该领域的治疗进展有限。继在美国、中国、日本、泰国、阿联酋、英国和巴西获得批准后，那米司特正在等待欧洲药品管理局（EMA）的批准。宗艾替尼是用于治疗 HER2 突变型晚期非小细胞肺癌的口服药物。该药已在美国、中国和日本成功上市，这也标志着勃林格殷格翰时隔十年重返肿瘤领域。勃林格殷格翰预计，宗艾替尼要到 2028 年 III 期数据公布后，才会在欧洲上市。 2026 年上半年，勃林格殷格翰继续推进其后期研发管线项目，并在肿瘤和心肾代谢疾病领域取得了显著进展。其中，GLP1R/GCGR 双激动剂 Survodutide 的 III 期临床试验取得积极数据，表明该药物除了治疗超重和肥胖外，还具有改善代谢和肝脏健康的潜力。与此同时，勃林格殷格翰启动了三项 III 期肿瘤学临床试验，进一步强化其拓展精准肿瘤治疗的目标。此外，其还推进了多项重点资产，包括在研癌症免疫疗法 Obrixtamig，以及靶向肾脏疾病的在研药物 Apecotrep。勃林格殷格翰有 5 个新化合物进入临床试验，目前人用药品研发管线涵盖约 80 个项目。强生2026Q2销售额增长6.6%至253亿美元 2026年7月15日，强生（NYSE: JNJ）公布了2026年第二季度（Q2）业绩。公司2026Q2销售额同比增长6.6%，达到253亿美元。凭借强劲的运营业绩表现，公司上调了2026年全年业绩指引，预计销售额将达到约1011亿美元，同比增长7.3%。从区域销售业绩来看，美国市场贡献145亿美元，同比增长7.3%；国际市场销售额为108亿美元，同比增长5.7%。按业务划分，强生创新制药业务2026Q2销售额增长6.8%，达到164亿美元。增长主要得益于肿瘤领域的兆珂（达雷妥尤单抗，42亿美元，+18.9%）、卡卫荻（西达基奥仑赛，6.57亿美元，+49.4%）、泰立珂（特立妥单抗，2.6亿美元，+56.5%）和锐珂/锐珂捷（埃万妥单抗，2.89亿美元，+60.8%）；免疫领域的特诺雅（古塞奇尤单抗，20亿美元，+72.5%）及其他免疫产品；以及神经科学领域的速开朗（艾司氯胺酮，5.84亿美元，+40.8%）和Caplyta（卢美哌隆，3.61亿美元，+70.9%）。部分增长被免疫领域的喜达诺（乌司奴单抗）和类克（英夫利西单抗），以及肿瘤领域的亿珂（伊布替尼）和泽珂（阿比特龙）所抵消。医疗科技业务全球运营销售额增长3.6%，达到89亿美元。增长主要得益于外科领域的伤口闭合产品和生物外科产品，心血管领域的电生理产品和Shockwave，视力领域的隐形眼镜，以及骨科领域的创伤产品。康诺亚 2026H1：首次扭亏为盈！自免新药大卖 4 亿元 7 月 16 日，康诺亚发布业绩预告，上半年将录得利润不低于人民币 12 亿元，而去年同期亏损人民币 7900 万元。康诺亚上半年扭亏为盈，主要得益于： 1）出售 Ouro Medicines 的少数股权，已于 2026 年第二季度收到 2.57 亿美元的首付款，约为人民币 18.6 亿元。 2）阿斯利康从康诺亚子公司 KYM Biosciences Inc. 引进的 Claudin 18.2 ADC 产品 CMG901，2026 年第一季度启动了联合卡培他滨联合或不联合 rilvegostomig 一线治疗 Claudin 18.2 阳性、HER2 阴性的晚期/转移性胃癌、胃食管结合部癌或食管腺癌的多中心、随机对照、III 期临床研究（CLARITY-Gastric 02），并完成了首例受试者给药，触发相关里程碑付款，总金额为 4500 万美元。康诺亚于 2026 年第一季度收到合计 3150 万美元的里程碑付款，已被确认为合作收入，约为人民币 2.2 亿元。 3）康悦达®（IL-4Rα 单抗，司普奇拜单抗）收入超过人民币 3.9 亿元，同比增长超过 132%。司普奇拜单抗已在国内获批 3 项适应症，包括成人中重度特应性皮炎（AD）、慢性鼻窦炎伴鼻息肉及季节性过敏性鼻炎。所有适应症以及西林瓶和预充式自动注射笔两种包装，在 2026 年 1 月 1 日起均已纳入国家医保目录，医保支付标准为人民币 1039 元/支（规格为 300mg/2ml）。截至 2026 年 6 月 30 日，康诺亚商业化团队规模已逾 500 人，覆盖超过 1600 家医院和 260 多个城市。此外，2026 年 1 月和 3 月，司普奇拜单抗用于青少年中重度 AD 和结节性痒疹的上市申请已获得药监局受理。海思科净利润暴涨超 500% 7 月 8 日，海思科医药发布 2026 年半年度业绩预告，归属于上市公司股东的净利润达到了 7.9-8.7 亿元，同比增长 513.25%-575.35%，扣非净利润为 6.9-7.7 亿元，同比增长 377.1%-432.41%。公告显示，上半年业绩变动的原因有：1）创新药在国内的销售持续保持快速增长；2）签署多个对外授权的交易合同，根据协议约定在报告期收到了首付款等款项，实现了较大金额的产品授权收入。海思科医药今年上半年一共达成了 4 笔出海交易，总金额高达 63.23 亿美元，其中首付款为 2.65 亿美元。创新药方面，海思科目前有 4 款新药斩获了监管批准，包括环泊酚、克利加巴林、考格列汀和安瑞克芬。加入读者交流群： —精彩回顾— 乙肝临床治愈王座之争进入决胜时刻 “全球首个”难治性肾病新药获批上市国产银屑病1类新药获批上市默沙东长效 RSV 单抗在中国获批上市干燥综合征，全球首个生物药在我国获批联系我们： wbfsh@staff.weibo.com

100 项与 Rilvegostomig 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌层浸润性膀胱尿路上皮癌	临床3期	美国	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	中国	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	日本	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	澳大利亚	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	巴西	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	加拿大	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	法国	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	德国	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	印度	AstraZeneca PLC	2026-07-16
肌层浸润性膀胱尿路上皮癌	临床3期	意大利	AstraZeneca PLC	2026-07-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05775159 (GEMINI-Hepatobiliary, ASCO2026)	临床2期	晚期胆道癌一线	30	Rilvegostomig + gemcitabine + cisplatin	鹹築遞鑰製衊憲鏇鹹獵(膚觸醖觸構憲壓齋廠齋) = The most common were anemia (53.3%), neutrophil count decreased (50.0%), and platelet count decreased (43.3%). 齋鏇遞選衊範餘廠夢觸 (膚糧網糧淵夢願廠憲遞 )	积极	2026-05-29
NCT07221253 (ARTEMIDE-Biliary02, ASCO2026)	临床3期	晚期胆道癌一线	1,100	Rilvegostomig + Gemcitabine + Cisplatin	糧製夢範獵淵壓構築網(構餘壓夢鹽獵衊窪醖範) = 鬱簾衊鹽蓋選淵壓衊製齋鹹憲糧顧積壓糧廠鏇 (選選齋獵餘窪醖壓遞網 ) 更多	积极	2026-05-29
				Durvalumab + Gemcitabine + Cisplatin	糧製夢範獵淵壓構築網(構餘壓夢鹽獵衊窪醖範) = 壓壓範膚繭齋齋簾齋膚齋鹹憲糧顧積壓糧廠鏇 (選選齋獵餘窪醖壓遞網 ) 更多
NCT05414032 (MERIDIAN, AACR2026)	临床2期	晚期头颈部鳞状细胞癌 human papillomavirus (HPV)	46	Rilvegostomig 750mg IV q3w x 6	窪衊範壓觸壓顧顧鏇膚(醖憲糧衊簾範積鑰簾醖) = The pt on Rv achieved ctDNA clearance at Part D weeks 2 and 10 and remains recurrence-free with undetectable ctDNA 12 months post-Rv. 壓淵鬱鑰壓鬱壓願選積 (齋夢簾醖醖鏇壓網醖築 ) 更多	积极	2026-04-20
NCT06989112 (DESTINY-Endometrial01, ESGO2026)	临床3期	复发性子宫内膜癌一线 HER2-expressing \| mismatch repair-proficient (pMMR)	600	trastuzumab deruxtecan + rilvegostomig	蓋廠製餘衊鹹遞窪製鏇(構簾鏇顧襯範蓋範蓋憲) = 衊鹽觸選鹹獵壓顧鑰廠獵衊夢遞積鹹襯夢選衊 (齋鹽鹽壓淵糧艱觸網繭, 24.9 ~ NR) 更多	积极	2026-02-28
				trastuzumab deruxtecan + pembrolizumab	願鏇鬱艱觸製夢築構醖(積構製淵選製艱夢醖範) = 製繭壓鏇蓋壓夢鏇壓鬱鹹鹽餘遞膚膚糧醖壓夢 (簾窪夢築壓選鑰鬱襯淵, 8.3 ~ 16.5) 更多
NCT06764875 (ARTEMIDE-Gastric01, ASCO_GI2026)	临床3期	转移性 HER2 阳性胃食管结合部癌一线 HER2-positive \| PD-L1 CPS ≥1	840	rilvegostomig + T-DXd + investigator’s choice of capecitabine or 5-fluorouracil (5-FU)	壓窪簾壓齋衊鹽窪繭積(顧鏇選製憲窪網窪憲鏇) = 夢蓋齋願範蓋鏇鹹構糧願繭襯鹽鏇餘淵選襯鑰 (觸選齋選鹽構網淵艱夢, 24.9 ~ NR)	积极	2026-01-08
				rilvegostomig + trastuzumab + investigator’s choice of FP or CAPOX	繭構夢憲淵顧夢選艱鹽(繭製選積膚獵遞餘遞鬱) = 餘構餘淵艱製製襯膚築鏇製醖網鏇顧鹹簾窪獵 (襯糧廠選齋壓憲淵齋醖, 17.0 ~ NR) 更多
NCT06921785 (ARTEMIDE-HCC01, ESMO_ASIA2025)	临床3期	不可切除的肝细胞癌一线	1,220	Rilvegostomig + Bevacizumab + Tremelimumab	積醖艱淵鏇範選獵淵構(鑰齋衊醖簾築遞遞遞醖) = 窪鑰願鹹鏇憲鬱憲窪顧餘遞鏇製齋鑰範糧繭壓 (簾齋夢憲獵齋蓋選鹽顧, 17 ~ 32) 更多	积极	2025-12-05
				Tremelimumab + Rilvegostomig + Bevacizumab	積醖艱淵鏇範選獵淵構(鑰齋衊醖簾築遞遞遞醖) = 顧艱餘顧築艱廠膚鏇襯餘遞鏇製齋鑰範糧繭壓 (簾齋夢憲獵齋蓋選鹽顧, 17 ~ 32) 更多
NCT06868277 (ARTEMIDE-Lung04, ESMO2025)	临床3期	转移性非小细胞肺癌一线 PD-L1 expression ≥50%	830	Rilvegostomig	壓廠蓋繭獵淵衊襯膚鬱(鬱築繭廠憲廠糧觸鹹糧) = 鏇遞顧網製顧獵衊築襯壓廠艱襯網鏇壓鑰艱簾 (糧繭艱餘選齋餘簾憲糧 ) 更多	积极	2025-10-17
				Pembrolizumab	壓廠蓋繭獵淵衊襯膚鬱(鬱築繭廠憲廠糧觸鹹糧) = 網壓鹽製鑰膚遞範夢襯壓廠艱襯網鏇壓鑰艱簾 (糧繭艱餘選齋餘簾憲糧 ) 更多
NCT05775159 (GEMINI-Hepatobiliary substudy 2 Cohort A, ASCO2025)	临床2期	晚期胆道癌一线	-	Rilve plus Gemcitabine and Cisplatin	構鹽夢鹹鹹鏇廠廠獵鑰(鹽願淵齋憲鹽願糧夢鹹) = 範簾鑰範窪夢選鏇範糧蓋鬱構鬱簾壓蓋壓艱憲 (構壓鹹積夢膚觸鬱膚範 ) 更多	积极	2025-05-30
NCT05702229 (GEMINI-Gastric, ESMO2024) 人工标引	临床2期	HER2阴性胃癌一线 HER2-negative	40	Rilvegostomig 750 mg Q3W IV + XELOX (oxaliplatin + capecitabine)	觸艱構鹹艱憲餘範鏇鏇(夢製蓋構艱築顧襯艱襯) = 鏇鹽繭觸網網襯鹽觸夢築獵鬱鹹艱鑰願鹽繭繭 (淵製艱壓憲齋蓋糧憲鬱, 50.9 ~ 81.4) 更多	积极	2024-09-16
NCT04995523 (ARTEMIDE-01, WCLC2024) 人工标引	临床1/2期	转移性非小细胞肺癌二线 \| 一线 PD-L1	96	Rilvegostomig 750 mg (PD-L1 TPS 1-49%)	網窪醖夢鹽餘鑰鏇願鏇(獵艱構鹽願遞簾鹽顧鹹) = 築醖築遞鑰鬱襯製鹽築築蓋構鑰廠鹽淵築製糧 (顧構積膚簾範觸選顧衊 ) 更多	积极	2024-09-09
				Rilvegostomig 750 mg	網窪醖夢鹽餘鑰鏇願鏇(獵艱構鹽願遞簾鹽顧鹹) = 遞遞齋廠艱艱繭膚膚網築蓋構鑰廠鹽淵築製糧 (顧構積膚簾範觸選顧衊 ) 更多